Sisram Med Ltd (SRAMF) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and good evening. Thank you everyone for joining us today. Welcome to CISRAM Medical's H1 2024 earnings call. This is Xiaotong Li, the analyst from Guangfa Securities. As a reminder, this conference call is being recorded today. Now I'd like to introduce our speakers on the call. With us on the line today are Mr. Leo Dayen, CISRAM Chief Executive Officer, Mr. Duran Yanai, AirMask DFO, Ms. Qianli Fang, Secretary of the Board. Management will begin with an overview of the business development for the H1 2024. And following the prepared remarks, we will hold a Q&A session. With that, I'd like to turn the conference over to Leo Dayen, CISROM's CEO, to share updates for H1 2024. Please go ahead. Thank you, Yeotong Li. Thank you very much, everybody, for joining us on the call today. I'm happy to provide an update on the ongoing success during the first half of 2024, which has been a period of momentum for CISROM. For over two decades, CISRM has been a global leader in the consumer wellness, built around four core businesses areas, which are energy-based devices, injectables, home-use devices, and also skincare. The medical aesthetic industry is evolving rapidly. Technological advancements and shifting consumer preferences are elevating beauty standards with increasingly sophisticated consumers seeking personalized and high-quality solutions. As the market expands with more practitioners entering the field, the demand for exceptional experiences and long-term patient care has never been higher. Within this dynamic landscape, I'm proud to update today that during the reporting period, CISRM achieved an all-time high new orders rate, demonstrating its unique value to growing audience of practitioners. This milestone, driven by rapid market adoption of Alma 3 r...